-
Innovation Ranking
NewInnovation Ranking – Pulmatrix Inc
Pulmatrix Inc (Pulmatrix) is a clinical stage biopharmaceutical company that discovers and develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline products using its proprietary dry powder delivery technology, iSPERSE. Its pipeline products include PUR1900, an anti-fungal compound which is in Phase 1 clinical trials intended to treat allergic bronchopulmonary aspergillosis in severe asthmatics and cystic fibrosis patients; PUR1800, a narrow-spectrum kinase inhibitor intended for the treatment of patients with...
-
Product Insights
Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Aspergillosis - Drugs In Development, 2023’, provides an overview of the Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Mycoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycoses - Drugs In Development, 2023’, provides an overview of the Mycoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Allergic Bronchopulmonary Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Bronchopulmonary Aspergillosis - Drugs In Development, 2023’, provides an overview of the Allergic Bronchopulmonary Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Bronchopulmonary Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Systemic Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Aspergillosis - Drugs In Development, 2023’, provides an overview of the Systemic Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Inhalers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Inhalers Pipeline Market Report Overview Inhalers deliver medication to the lungs. The inhalers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segment ·       Dry Powder Inhaler Devices Key Territories ·       The US ·       Europe ·       Australia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DD-01 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DD-01 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DD-01 in Type 2 Diabetes Drug Details: DD-01 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Itraconazole in Asthma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Itraconazole in Asthma Drug Details: Itraconazole is under development for the treatment of allergic/invasive aspergillosis infections,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darolutamide in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Darolutamide in Triple-Negative Breast Cancer (TNBC) Drug Details:Darolutamide (Nubeqa) is a nonsteroidal antiandrogen with potential anti...